RMD: Financial results · Company disclosure

Item 2.02. Results of Operations and Financial Condition. On July 7, 2026, ResMed Inc. (the “Company” or “Resmed”) issued a press release announcing that on June 30, 2026 it entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on healthcare. The $490 million all-cash transaction, subject to certain closing adjustments, is expected to close during the first quarter of Resmed’s fiscal year 2027, subject to required regulatory approvals and customary closing conditions. Resmed intends to use net proceeds from the transaction to return capital to shareholders, including through an accelerated share repurchase (ASR) program, and for general corporate purposes. Resmed and Frazier Healthcare Partners expect to enter into transition services agreements (“TSAs”) to facilitate continuity across systems, processes, tools, and day-to-day operations. These TSAs will largely offset stranded costs in the first-year post-closing. Resmed intends to mitigate and eliminate any remaining stranded costs over time. Based on preliminary financial results for the full fiscal year 2026, the MatrixCare business represented approximately $220 million of revenue and approximately $55 million of non-GAAP operating profit. In addition to the MatrixCare business-related financial considerations, Resmed’s recently completed Noctrix acquisition is expected to contribute approximately $30 million of revenue and reduce non-GAAP diluted EPS by approximately $0.20 in fiscal year 2027. Resmed continues to expect its Residential Care Software (RCS) segment to accelerate to high single digit percentage year-over-year revenue growth, along with operating leverage, in fiscal year 2027. Resmed will provide its full fiscal ye